Pfizer and Astellar's prostate cancer treatment Xtandi has been approved by the US FDA
白云追月素
发表于 2023-11-17 14:23:09
219
0
0
On November 16th, Pfizer and Astellar jointly announced that their prostate cancer drug XTANDI has been approved by the US Food and Drug Administration (FDA) for the treatment of non metastatic castration sensitive prostate cancer (nmCSPC) patients. XTANDI is currently undergoing review by other regulatory agencies, including the European Medicines Agency. Xtandi is an androgen receptor signaling inhibitor that has received regulatory approval in multiple countries and regions around the world.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Shortly after delivering the 14th car, FF launched its second brand! Jia Yueting: Price announcement for a popular product that offers "twice the performance, half the price" for American users!
- China Photovoltaic Industry Association: The United States provides a large amount of photovoltaic subsidies in violation of regulations, distorting the global photovoltaic market
- The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
- Smoke suspected in cockpit, US plane with 130 passengers makes emergency landing
- California accuses ExxonMobil of misleading the public on plastic recycling issues
- 2024Q2 US PC Report: HP up 3.7% YoY, Dell down 5.8%, Lenovo up 7.7%, Apple up 0.5%, Acer up 19.8%
- The United States plans to ban key software and hardware from China, and General Motors and Ford may stop importing some models
- Abandon polls! Wall Street analyst: Predicting US beauty pageant stocks is more reliable!
- Suddenly in the United States! Strike storm! Major risk escalation! How significant is the impact?
- Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 前天 14:17
- 支持
- 反对
- 回复
- 收藏
-
10月1日、理想自動車が9月に納入したデータによると、9月に理想自動車が新車53709台を納入し、前年同月比48.9%増となった。 今年第3四半期、理想自動車は前年同期比45.4%増の152831台を納入した。今年9月30日現在、 ...
- 就放荡不羁就h
- 20 分钟前
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 前天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 3 天前
- 支持
- 反对
- 回复
- 收藏